Dr. Carbone, the Chief Scientific Officer (CSO) of Tethis, holds a Ph.D. in Forensic Medicine and recently completed a Master's Degree in Technology and Innovation. With an extensive background in life sciences, research and development, she has a passion for driving innovation in the field. Dr. Carbone has gained significant experience during her tenure at prestigious institutions, including several years at the National Institute of Health in Bethesda, USA, and a decade at the European Institute of Oncology in Milan, Italy. Her research has primarily focused on technological development and innovation in oncology.
At Tethis, one of her most notable achievements was the successful market introduction of a groundbreaking diagnostic device for analyzing genetic diseases by FISH. Currently, she is spearheading the development of the diagnostic workflow for the liquid biopsy project, a cutting-edge initiative aimed at revolutionizing cancer diagnostics.
Dr. Carbone has co-authored more than 30 peer-reviewed publications and is the lead inventor on several patents, underscoring her contributions to the advancement of medical technology and her commitment to improving patient outcomes.

As the Global Director for Lung Diagnostics and Liquid Biopsy Strategy, Ryan supports both the lung cancer biomarker strategy for the current and future AstraZeneca therapeutic portfolio, as well as the broader Global Commercial Diagnostics strategy for liquid biopsy, across tumor types. Ryan has over 15 years’ experience in the molecular diagnostics space and has held a variety of roles in the areas of research and development, commercial leadership and strategy and partnerships. Ryan holds a Masters of Science in Molecular Biophysics degree from the University of Guelph.

Dr. Marc Eid is a postdoctoral research fellow in Medical Oncology at the Dana-Farber Cancer Institute in Boston, USA. He earned his Medical Doctor (MD) degree and master of science (MS) degree in cancer biology from the Faculty of Medicine, Saint Joseph University of Beirut, Lebanon. In his current role, Dr. Eid studies novel epigenomic liquid biopsy tools that can be leveraged to impact patient care.

Dr. Dominic Rose is a Next-Generation Sequencing (NGS) enthusiast associated with Roche Diagnostics. In his current role as Senior Application Specialist he is responsible for the sequencing bioinformatics portfolio of Roche Diagnostics in the Region EMEA-LATAM. He received his PhD in Bioinformatics from the University of Leipzig, Germany. He gained several years of experience in leading high-throughput diagnostic environments such as the Munich Leukemia Laboratory where he implemented state of the art sequencing assays and bioinformatic workflows. With the idea in mind to bring NGS closer to the clinics and to the patient he joined Roche Diagnostics in 2016 to further shape genomics based precision oncology.

 

Dr. Dominic Rose is a Next-Generation Sequencing (NGS) enthusiast associated with Roche Diagnostics. In his current role as Senior Application Specialist he is responsible for the sequencing bioinformatics portfolio of Roche Diagnostics in the Region EMEA-LATAM. He received his PhD in Bioinformatics from the University of Leipzig, Germany. He gained several years of experience in leading high-throughput diagnostic environments such as the Munich Leukemia Laboratory where he implemented state of the art sequencing assays and bioinformatic workflows. With the idea in mind to bring NGS closer to the clinics and to the patient he joined Roche Diagnostics in 2016 to further shape genomics based precision oncology.